Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PRTA's Cash to Debt is ranked higher than
91% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: 34.92 vs. PRTA: No Debt )
PRTA' s 10-Year Cash to Debt Range
Min: 9999   Max: No Debt
Current: No Debt

Equity to Asset 0.95
PRTA's Equity to Asset is ranked higher than
97% of the 1122 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. PRTA: 0.95 )
PRTA' s 10-Year Equity to Asset Range
Min: -1.78   Max: 0.98
Current: 0.95

-1.78
0.98
Interest Coverage No Debt
PRTA's Interest Coverage is ranked higher than
83% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PRTA: No Debt )
PRTA' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 43.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -13.07
PRTA's Operating margin (%) is ranked higher than
81% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. PRTA: -13.07 )
PRTA' s 10-Year Operating margin (%) Range
Min: -5980.33   Max: -13.07
Current: -13.07

-5980.33
-13.07
Net-margin (%) -14.06
PRTA's Net-margin (%) is ranked higher than
79% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. PRTA: -14.06 )
PRTA' s 10-Year Net-margin (%) Range
Min: -6064.5   Max: -14.06
Current: -14.06

-6064.5
-14.06
ROE (%) -2.85
PRTA's ROE (%) is ranked higher than
83% of the 1339 Companies
in the Global Biotechnology industry.

( Industry Median: -30.19 vs. PRTA: -2.85 )
PRTA' s 10-Year ROE (%) Range
Min: -68.99   Max: -3.09
Current: -2.85

-68.99
-3.09
ROA (%) -2.72
PRTA's ROA (%) is ranked higher than
84% of the 1463 Companies
in the Global Biotechnology industry.

( Industry Median: -24.77 vs. PRTA: -2.72 )
PRTA' s 10-Year ROA (%) Range
Min: -62.32   Max: -2.94
Current: -2.72

-62.32
-2.94
ROC (Joel Greenblatt) (%) -203.36
PRTA's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 1426 Companies
in the Global Biotechnology industry.

( Industry Median: -347.18 vs. PRTA: -203.36 )
PRTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2440.91   Max: -204.81
Current: -203.36

-2440.91
-204.81
» PRTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

PRTA Guru Trades in Q2 2014

Paul Tudor Jones 30,549 sh (New)
Leon Cooperman 100,000 sh (New)
Vanguard Health Care Fund 1,662,794 sh (+25.26%)
Jim Simons 51,900 sh (-34.40%)
» More
Q3 2014

PRTA Guru Trades in Q3 2014

Vanguard Health Care Fund 1,662,794 sh (unchged)
Paul Tudor Jones Sold Out
Leon Cooperman 80,000 sh (-20.00%)
Jim Simons 17,300 sh (-66.67%)
» More
Q4 2014

PRTA Guru Trades in Q4 2014

Vanguard Health Care Fund 1,662,794 sh (unchged)
Jim Simons Sold Out
Leon Cooperman Sold Out
» More
Q1 2015

PRTA Guru Trades in Q1 2015

Vanguard Health Care Fund 1,662,794 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PRTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.30
PRTA's P/B is ranked higher than
77% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 6.95 vs. PRTA: 3.30 )
PRTA' s 10-Year P/B Range
Min: 0.84   Max: 5.16
Current: 3.3

0.84
5.16
P/S 16.33
PRTA's P/S is ranked higher than
65% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 37.39 vs. PRTA: 16.33 )
PRTA' s 10-Year P/S Range
Min: 8.29   Max: 900.25
Current: 16.33

8.29
900.25
PFCF 266.00
PRTA's PFCF is ranked higher than
88% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PRTA: 266.00 )
PRTA' s 10-Year PFCF Range
Min: 139.62   Max: 297.38
Current: 266

139.62
297.38
POCF 259.79
PRTA's POCF is ranked higher than
88% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. PRTA: 259.79 )
PRTA' s 10-Year POCF Range
Min: 129.64   Max: 2363
Current: 259.79

129.64
2363
Current Ratio 24.86
PRTA's Current Ratio is ranked higher than
96% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. PRTA: 24.86 )
PRTA' s 10-Year Current Ratio Range
Min: 0.01   Max: 72.16
Current: 24.86

0.01
72.16
Quick Ratio 24.86
PRTA's Quick Ratio is ranked higher than
97% of the 1451 Companies
in the Global Biotechnology industry.

( Industry Median: 4.12 vs. PRTA: 24.86 )
PRTA' s 10-Year Quick Ratio Range
Min: 0.01   Max: 72.16
Current: 24.86

0.01
72.16
Days Sales Outstanding 12.41
PRTA's Days Sales Outstanding is ranked higher than
96% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. PRTA: 12.41 )
PRTA' s 10-Year Days Sales Outstanding Range
Min: 12.41   Max: 31.32
Current: 12.41

12.41
31.32

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.30
PRTA's Price/Net Cash is ranked higher than
93% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 86.70 vs. PRTA: 3.30 )
PRTA' s 10-Year Price/Net Cash Range
Min: 1.06   Max: 3.46
Current: 3.3

1.06
3.46
Price/Net Current Asset Value 3.30
PRTA's Price/Net Current Asset Value is ranked higher than
93% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 39.00 vs. PRTA: 3.30 )
PRTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.05   Max: 3.43
Current: 3.3

1.05
3.43
Price/Tangible Book 3.20
PRTA's Price/Tangible Book is ranked higher than
85% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. PRTA: 3.20 )
PRTA' s 10-Year Price/Tangible Book Range
Min: 1   Max: 4.35
Current: 3.2

1
4.35
Price/Median PS Value 0.50
PRTA's Price/Median PS Value is ranked higher than
96% of the 1626 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. PRTA: 0.50 )
PRTA' s 10-Year Price/Median PS Value Range
Min: 0.66   Max: 46.53
Current: 0.5

0.66
46.53
Earnings Yield (Greenblatt) -0.90
PRTA's Earnings Yield (Greenblatt) is ranked higher than
81% of the 1417 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. PRTA: -0.90 )
PRTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.9   Max: 74709.2
Current: -0.9

-0.9
74709.2

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0PT.Germany,
Prothena Corporation PLC was incorporated in Ireland as a private limited company under the name Neotope Corporation Limited on September 26, 2012. On November1, 2012, it changed the name of the company to Prothena Corporation plc. It is a biotechnology company engaged in the discovery and development of novel antibodies for the potential treatment of an array of diseases that involve protein misfolding or cell adhesion. Its research and development pipeline includes three main therapeutic antibody programs: NEOD001 for the treatment of AL and AA Amyloidosis; PRX002 (formerly NEOD002) for the treatment of Parkinson's disease; and PRX003 for the potential treatment of inflammatory disease and metastatic cancers. Its pipeline also includes two late discovery stage programs: tau antibodies for potential treatment of Alzheimer's disease and antibodies for the potential treatment of type 2 diabetes. The competitors consist of major international companies, all of which are larger and have greater financial resources, technical staff, manufacturing, R&D and marketing capabilities. It also competes with smaller research companies and generic drug and biosimilar manufacturers. It is subject to significant regulation by international, national, state and local governmental regulatory agencies.
» More Articles for PRTA

Headlines

Articles On GuruFocus.com
Prothena (PRTA) Potential Parkinson's Treatment, Envivio (ENVI) Improved Results, Nike (NKE) Profita Mar 20 2015 
Three Stocks With Massive Insider Buying Sep 03 2014 

More From Other Websites
What's in Store for Prothena (PRTA) this Earnings Season? - Analyst Blog May 01 2015
Prothena to Present at Upcoming Investor Healthcare Conferences Apr 28 2015
Prothena to Present at Upcoming Investor Healthcare Conferences Apr 28 2015
Prothena to Present at Upcoming Investor Healthcare Conferences Apr 28 2015
Dr. Dale Schenk to Participate on Expert Panel at World Medical Innovation Forum: Neurosciences Apr 23 2015
Dr. Dale Schenk to Participate on Expert Panel at World Medical Innovation Forum: Neurosciences Apr 23 2015
PROTHENA CORP PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 13 2015
Prothena (PRTA) Stock Declines Today on Pricing of Secondary Offering Apr 08 2015
Prothena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares Apr 08 2015
Prothena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares Apr 08 2015
Prothena Announces Pricing of Public Offering of 3,300,000 Ordinary Shares Apr 08 2015
Investing in brain health: Ex-NFL star Apr 07 2015
Clovis Cancer 'Breakthrough,' Oculus Flop Top Biotech News Late Apr 06 2015
Prothena Announces Proposed Offering of Ordinary Shares Apr 06 2015
Prothena Announces Proposed Offering of Ordinary Shares Apr 06 2015
Prothena Announces Proposed Offering of Ordinary Shares Apr 06 2015
Can the Uptrend Continue for Prothena (PRTA)? - Tale of the Tape Mar 30 2015
The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases Mar 26 2015
Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst... Mar 25 2015
PROTHENA CORP PLC Files SEC form 8-K, Regulation FD Disclosure Mar 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK